Natera, Inc. (NTRA)
Nasdaq · Common stock · Services-Medical Laboratories
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow NTRA in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on NTRA and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
NTRA at a glance
Key statistics
$58.51B
Market capitalization
- Previous close
- $405.92
- Open
- $406.40
- Day range
- $404.73 – $419.87
- Volume
- 679.4K
- Average volume (30 sessions)
- 1.68M
- Shares outstanding
- 144.14M
- Earnings per share
- $(1.33)
- Price / book
- 32.1
- Price / sales
- 21.6
- Beta (1 year, vs SPY)
- 1.25
Where the price sits in its year
52-week range
93% of the range
- Below the 52-week high
- -4.4%
- Above the 52-week low
- +131.1%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $403.78+0.5%
- 50-day average
- $361.38+12.3%
- 200-day average
- $259.23+56.6%
Between the conventional 30 and 70 bands.
+2.6%
1 week
+9.5%
1 month
+53.6%
3 months
+77.2%
Year to date
+123.4%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with NTRA
NTRA on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on NTRA.
See the plans →
Every planScreen names like NTRA
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on NTRA
Put NTRA on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on NTRA
See whether there is an open premium alert on NTRA, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
NTRA headlines
- Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst
Benzinga · Apr 14, 2026
- Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Benzinga · Mar 31, 2026
- Natera New Test Data Could Change How Doctors Manage Breast Cancer
Benzinga · Dec 11, 2025
- Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Benzinga · Dec 5, 2025
- Natera Buys Foresight To Boost Super-Early Cancer Detection Tech
Benzinga · Dec 5, 2025
- Natera executive sells shares worth over $57k - Investing.com
Investing.com · Jul 23, 2024
- Breaking Down Natera: 10 Analysts Share Their Views
Benzinga · Jun 3, 2024
- Key Takeaways From Natera Analyst Ratings
Benzinga · May 13, 2024
SEC Form 4, most recent first
Insider filings
Sheena Jonathan
−60
Director · Open-market sale
$24.10K · Oct 16, 2026
Sheena Jonathan
−80
Director · Open-market sale
$32.48K · Oct 16, 2026
Sheena Jonathan
−90
Director · Open-market sale
$36.33K · Oct 16, 2026
Sheena Jonathan
−215
Director · Open-market sale
$85.86K · Oct 16, 2026
Sheena Jonathan
−280
Director · Open-market sale
$112.19K · Oct 16, 2026
Sheena Jonathan
−90
Director · Open-market sale
$36.38K · Oct 16, 2026
Sheena Jonathan
−142
Director · Open-market sale
$56.65K · Oct 16, 2026
Sheena Jonathan
−280
Director · Open-market sale
$112.36K · Oct 16, 2026
About Natera, Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Services-Medical Laboratories
- Headquarters
- Austin, TX
- Employees
- 6,140
- Listed since
- Jul 2, 2015
- Website
- natera.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.